

WORKING
TOGETHER

...

Profiles of Collaboration



Alzheimer's disease (AD) is a tragic loss-of-mind illness that affects 1 of every 4 people over age 75, and their caregivers. It also takes an enormous toll on society. At over \$100 billion per year, AD is the third most costly disease in the U.S. after heart disease and cancer. Currently, 18 million cases have been reported worldwide. In the coming years, with baby boomers aging, the number of cases will triple. The devastating personal and societal costs of AD can be reduced by developing new drugs. With just 4 modestly effective drugs on the market today that only treat the symptoms of the disease but not the cause, it is imperative that our research efforts be accelerated.

THE URGENT NEED FOR DRUGS

S I G N I F I C A N C E



While basic research generally funded by foundations and government seeks to find the causes of AD, new treatments come from drug discovery research, where chemical compounds that will be used for pills are created. Developing effective AD drugs will enable older persons to die with dignity and save billions in healthcare costs. This is an achievable goal. The Institute for the Study of Aging (ISOA), an Estée Lauder family foundation founded in 1998, and the Alzheimer's Drug Discovery Foundation (ADDF), an affiliated public charity established in 2004, are committed to funding the development of new treatments for AD through venture philanthropy.



DISCOVERY

Frank Longo, MD, PhD Professor and Chair, Stanford University Department of Neurology and Neurological Sciences



Neurotrophins are naturally occurring proteins that can prevent and treat neuronal degeneration. These proteins are too large to be taken orally or to adequately penetrate the central nervous system to be useful as drugs. The development of small compounds that mimic the key parts of neurotrophins has been a much sought after goal. Support from the Institute for the Study of Aging (ISOA) allowed us to launch a high risk program in which we applied advanced drug modeling to develop the first drug-like small molecules capable of preventing neural degeneration.

EVALUATING RISKS AND REWARDS

S U P P O R T



Given the high risk, but potentially high yield, approach of our research, it was quite difficult to obtain funding. The ISOA has created an exceptional vehicle for funding where risks and benefits of innovative drug discovery programs are explored in depth and in the context of translational research that is very different from traditional foundations. In addition to their financial support, ISOA provides expert technical assistance that is unparalleled to any other philanthropic organization. With their help, my lab is now testing our drug-like molecules in mice with AD.

P H I L A N T H R O P Y



Jordan Tang, PhD Chief Scientific Officer of Zapaq, and Chair of Medical Research, Oklahoma Medical Research Foundation



Beta-secretase has long been recognized as a main therapeutic target for the development of drugs to treat AD. When my laboratory cloned beta-secretase and determined its basic properties, the stage was set for actual drug development. We recognized that such development would require organization and funding. Together with Arun Ghosh, we founded a biotechnology company named Zapaq, with the mission to develop beta-secretase inhibitor drugs. One of two initial sources of seed funding came from the ISOA.

BRINGING NEW DRUGS TO MARKET



Their funding was critical for Zapaq because it allowed us to obtain business and legal assistance in setting up the framework of the company. It also helped us to recruit key scientists and begin our research program, as well as seek follow-on funding. Today, at three-years-old, Zapaq has stable financing from venture capital companies. Its research team has used structure-based design to attain advanced drug candidates. Such programs afford optimism that a drug candidate will be tested in human clinical trials in the near future. Without ISOA's assistance, it would have been difficult for our company to come into existence.



COLLABORATION

Kelly Martin President & Chief Executive Officer, Elan Pharmaceuticals, Inc.



Elan Pharmaceuticals is proud to be working with the Alzheimer's Drug Discovery Foundation (ADDF), an ISOA affiliated public charity, to support innovative drug discovery for AD. The program that we collaboratively launched in 2005, *Novel Approaches to Drug Discovery for Alzheimer's Disease*, seeks to identify and fund promising research in academic and biotech labs around the world. Alliances such as these, among biotechnology companies, philanthropies and academic institutions, are crucial to accelerating breakthrough therapies for AD.

CREATING OPPORTUNITIES FOR SUCCESS




The ADDF utilizes a unique venture philanthropy model focused on drug discovery. For over 20 years, Elan has also invested in adopting original approaches to disease modification in neurodegenerative diseases like AD. We have a common goal — to help end the life-shattering disease that not only impacts patients but also their loved ones. When we can combine our passion, energy and ingenuity, we create the opportunity to advance towards providing a cure. By joining forces, we are increasing the chances of success and ultimately benefiting millions of people.

MESSAGE FROM ADDF CO-CHAIRPERSONS



Ronald Lauder
Co-Chairperson & Director



Leonard Lauder
Co-Chairperson & Director

When we started the ISOA in 1998, our goal was to create a family foundation that would fund scientists pursuing drug discovery research for AD in hopes that we could find a better way to prevent and treat this horrific disease. Through expert leadership, our Executive Director Howard Fillit, MD, has proven that providing this funding is not only necessary, but it also serves as a catalyst for scientists worldwide.

Over the years, requests for funding grew to the point where we were only able to support less than 10 percent of the proposals we received. With so many good ideas for new drugs going unfunded, we decided it was time to invite others to work with us.

During spring 2004, we founded a public charity called the Alzheimer's Drug Discovery Foundation (ADDF). By fall, we began in earnest to build partnerships. The response was extraordinary, making 2005 a banner year of growth. We collaborated with several key organizations and raised awareness about the importance of funding AD drug discovery.

In working with our new Board of Directors, who each have a personal connection to AD, we are developing innovative ways to educate the general public. As we have learned over the past year, our best approach to conquering AD is through working together. We encourage you to join us.

MESSAGE FROM ADDF PRESIDENT



Nancy Corzine
President & Director

During the 8 years that I was the primary caregiver for my beloved mother, I saw AD progress through many stages. At first, I wondered why this wonderful woman was changing and becoming a stranger to me. Then, the disease became more obvious. Finally, it totally enveloped her and took her from me.

When I heard about ISOA and their sole mission of funding drug discovery research for AD, I was very impressed. As I learned more about their accomplishments it led me to think that this was the type of organization that I should align with, to do whatever I can in the fight against this dreaded disease.

Since becoming President of the ADDF Board of Directors, it has been my vision to inspire people who have witnessed the tragedy of AD to work with us. We also need to increase the public's awareness and understanding of why drug discovery is important to finding a cure; and the degree to which AD impacts patients, families, our healthcare system and economy.

I look forward to working with others whose goals are similar to mine. The only way we can end the nightmare of AD is to collectively support scientists in their research efforts to discover and develop new drugs.

ADDF BOARD MEMBERS



“Losing my mother to AD over 7 years was difficult to watch. The sad fact was this vibrant lady slowly left me and there was nothing I could do. In my effort to get even, I discovered the ADDF. Driven by a singular mission and relentless professional management, ADDF is the most effective charity working towards solving one of the most challenging diseases of the 21st Century.”

John Cooney
Director

John Cooney is a private investor who was Founder and Chief Executive Officer of CRC Incorporated, the largest independently owned property and casualty insurance wholesaler in the United States. In 2002, CRC was sold to BBT, America’s 9th largest bank holding company. Mr. Cooney earned his BS degree in Business from Samford University of Birmingham, AL. He and wife Liz reside in Alabama, New York and Switzerland.

“Having someone close to me recently diagnosed with dementia has changed my life. Learning about the ADDF and meeting others who have witnessed this loss-of-mind illness has been a blessing. Now that I have a better understanding of memory loss diseases, I am determined to make a difference. Working with the ADDF Board to fund those on the cutting edge of a cure is my top priority.”

Joy Fishman
Director

Joy Fishman is the former Executive Director of the Pritikin Longevity Center of Miami Beach, where she oversaw the operations of the world famous diet and exercise program. Ms. Fishman holds a MS degree in Psychotherapy and a BS degree in Psychology from Barry University of Miami, FL. She and husband Jack reside in New York and Florida.



“One of the last unmet medical needs in our society is a disease-modifying drug for AD. The ADDF dedicates itself toward this goal, which will improve the quality of life for millions of people. With my personal knowledge of AD and my experience in the venture capital arena, I believe that I can help the ADDF, but it will take more than a few of us to succeed. Join us in funding this important goal.”

Robert McNeil, PhD
Director


Robert McNeil, PhD, has over 25 years experience as an investor and management participant in seed and early-stage biomedical companies. He founded Sanderling Ventures in 1979, and serves as its Managing Director and Chair of the Partnership Committee. Dr. McNeil earned his PhD in molecular biology, biochemistry and genetics from the University of California, Irvine. He and wife Deborah reside in California and Maine.

“ I think ADDF’s investment model is a brilliant way to run a public charity. Using for-profit business practices and recycling return on investment is a smart strategy for making the most out of limited dollars. Knowing how AD has affected my wife’s family, it made sense to join forces with the ADDF Board and help them increase their likelihood of success. I welcome others to do the same.”

Jon Rotenstreich
Director

Jon Rotenstreich is a managing partner of RF Partners, a financial consulting and investment firm. He is also the founding principal and Chairman of Bayer Properties, a real estate development company. Mr. Rotenstreich is a graduate of the University of Alabama (UA) and sits on many boards including UA’s President’s Cabinet. He and wife Susan reside in New York and Wyoming.

MESSAGE FROM THE EXECUTIVE DIRECTOR



Howard Fillit, MD
Executive Director

ISOA and ADDF share a common mission: to fund drug discovery for AD and cognitive aging. Employing a biomedical venture philanthropy model since 1998, we have awarded \$24 million for 143 programs and conferences worldwide.

Results show that our model works. ISOA-funded scientists created new classes of drugs in development for AD, screened millions of compounds, identified hundreds of leads, and demonstrated pre-clinical proof-of-concept. Their programs advanced from early-stage chemistry to clinical trials, licensing deals, company formation, late-stage financing, and public offerings. We have also received returns on our investments.

A prime example is Allon Therapeutics, Inc. After awarding a pre-clinical discovery research grant to Illana Gozes, PhD, at Tel Aviv University and receiving promising outcomes, we gave her strategic management assistance and a loan of \$253,100 to found Allon in 2002. Today, the company is trading on the Toronto Stock Exchange and conducting Phase II clinical trials for AD and cognitive impairment after coronary artery bypass surgery. In December 2005, ISOA received the return of its loan and recycled it for other research.

Unfortunately, \$24 million is not enough, and ISOA cannot fund the vast majority of proposals it receives. So we founded the ADDF in 2004 to enable the public to work with us. ISOA pays 90 percent of ADDF's overhead, ensuring that all donations directly fund drug discovery research. This private foundation-public charity partnership proved highly effective in 2005.

ADDF IS AN ORGANIZATION OF

entrepreneurs

DEDICATED TO ACCELERATING AD DRUG DISCOVERY


THROUGH VENTURE PHILANTHROPY.

We collaborated with Elan Pharmaceuticals to advance our mutual mission of discovering new drugs for AD. The program received an overwhelming response of 45 proposals from 12 countries, but we were only able to fund 4. We also partnered with the National Institute on Aging (NIA) and established another AD drug discovery program that received 45 proposals. The NIA funded 5 and we will fund 3. These responses underscore the great need for funding.

We are concerned about preventing cognitive decline as well as AD. To promote cognitive health in elderly persons, we partnered with PacfiCare Health Systems to create a Cognitive Vitality Program that is now available to 180,000 people. To improve the care of AD patients, we are developing clinical practice guidelines with funding from Forest Laboratories.

We established the ADDF Board of Directors, Advisory Council and Business Development Committee, and are thankful for their commitment. We were fortunate to have many corporations, foundations and individuals contributing to our first fundraising program, resulting in raising almost \$2.5 million.

As a geriatrician who has cared for thousands of people with AD, I know the tremendous burden of this illness. As a neuroscientist, I am certain that we can successfully develop effective AD drugs within 5-10 years. This historic accomplishment will transform human aging. We need your help to insure that it happens.



ISOA BOARD OF DIRECTORS

ESTÉE LAUDER
*Founder and
Honorary Director*

LEONARD A. LAUDER
Co-President and Director

RONALD S. LAUDER
Co-President and Director

HOWARD FILLIT, MD
*Executive Director
and Director*

SUZANNE GROSSBERG, MA
Secretary

JOAN KRUPSKAS
Treasurer

ROBERT N. BUTLER, MD
Director

BARBARA J. DALTON, PhD
Director

LANNY EDELSON, MD
Director

ALLAN GREEN, MD, PhD, JD
Director

JULIA P. GREGORY
Director

ELIAS K. MICHAELIS, MD, PhD
Director

•••

ADDF BOARD OF DIRECTORS

LEONARD A. LAUDER
Co-Chairperson and Director

RONALD S. LAUDER
Co-Chairperson and Director

NANCY CORZINE
President and Director

HOWARD FILLIT, MD
*Executive Director
and Director*

SUZANNE GROSSBERG, MA
Secretary

JOAN KRUPSKAS
Treasurer

JOHN COONEY
Director

JOY FISHMAN
Director

ROBERT McNEIL, PhD
Director

JON ROTENSTREICH
Director

•••

ADDF ADVISORY COUNCIL

HOWARD COX
*Partner
Greylock*

JOHN ROWE, MD
*President and
Chief Executive Officer
Aetna, Inc.*

ANDREW SCHIFF, MD
*Managing Director
Perseus-Sorros
Biopharmaceutical Fund, L.P.*

•••

ADDF BUSINESS DEVELOPMENT COMMITTEE

NANCY CORZINE – CHAIR
HOWARD FILLIT, MD

LIZ COONEY
JOY FISHMAN
SUZANNE GROSSBERG, MA

MONIKA HALAREWICZ
KATE FURMAN PASIK
LESLYE SUGAR

SUSAN TANE
AMY TREITEL

•••

STAFF

HOWARD M. FILLIT, MD
Executive Director

SUZANNE GROSSBERG, MA
Director of Development

FILOMENA GOMES
Grants Writer

PEGGY QUIROZ
Executive Coordinator

MONIKA HALAREWICZ
Communications Associate

WENDY RAMOS
Grants and Database Manager

•••

SCIENTIFIC REVIEW BOARD

PAUL S. AISEN, MD
*Georgetown University
Medical Center
Washington, DC*

OTTAVIO ARANCIO, MD, PhD
*Columbia University
New York, NY*

THEODORE BASHORE, PhD
*University of Northern
Colorado
Greeley, CO*

COLIN B. BIER, PhD
*ABA BioResearch Inc.
Ville St. Laurent
Quebec, Canada*

LARRY D. ALTSTIEL, MD, PhD
*Schwarz Biosciences, Inc.
Research Triangle Park, NC*

SANJAY ASTHANA, MD
*University of Wisconsin
Madison Medical School
Madison, WI*

PAUL E. BENDHEIM, MD
*Banner Good Samaritan
Medical Center
Phoenix, AZ*

LESTER I. BINDER, PhD
*Northwestern University
Medical School
Chicago, IL*

JAMES E. BIRREN, PhD
*UCLA Center on Aging
Los Angeles, CA*

ROBERTA DIAZ BRINTON, PhD
*University of Southern
California
Los Angeles, CA*

JERRY BUCCAFUSCO, PhD
*Prime Behavior Testing
Laboratories, Inc.
Augusta, GA*

LUC BUEE, PhD
*INSERM U422 (French
National Institute for Health
and Medical Research)
Lille, France*

ANTHONY CERAMI, PhD
*Warren Pharmaceuticals
Ossining, NY*

GREG M. COLE, PhD
*VA Medical Center
Sepulveda, CA*

JOSEPH T. COYLE, MD
*Harvard Medical School
Belmont, MA*

SUZANNE CRAFT, PhD
*Seattle Institute for Biomedical
and Clinical Research
Seattle, WA*

KEITH A. CRUTCHER, PhD
*University of Cincinnati
Cincinnati, OH*

JEFFREY L. CUMMINGS, MD
*UCLA School of Medicine
Los Angeles, CA*

CHARLES S. DeCARLI, MD
*University of California, Davis
Sacramento, CA*

RICHARD Di ROCCO, PhD, LLC
Secant Pharma

KAREN DUFF, PhD
*Nathan Kline Institute
Orangeburg, NY*

CHRISTOPHER B. ECKMAN, PhD
*Mayo Clinic Jacksonville
Jacksonville, FL*

ELIZABETH EDGERLY, PhD
*Alzheimer's Association of
Northern California and
Northern Nevada
Mountain View, CA*

ALAN FADEN, MD
*Georgetown University School
of Medicine
Washington, DC*

HOWARD FELDMAN, MD
*University of British
Columbia Hospital
Vancouver, BC
Canada*

KEVIN FELSENSTEIN, PhD
*Johnson & Johnson
Pharmaceutical Research &
Development
Titusville, NJ*

AVRAHAM FISHER, PhD
*Israel Institute for
Biological Research
Ness-Ziona, Israel*

NICHOLAS CHARLES ILYA FOX, PhD
*Dementia Research Centre
London, UK*

BLAS FRANGIONE, MD, PhD
*NYU School of Medicine
New York, NY*

RICHARD A. FRANK, MD, PhD
*GE Healthcare
Princeton, NJ*

PAUL E. FRASER, PhD
*University of Toronto
Toronto, Ontario
Canada*

ROBERT P. FRIEDLAND, MD
*Case Western Reserve University
School of Medicine
Cleveland, OH*

GEORGE FULOP, MD
*Needham & Company, Inc.
New York, NY*

DOUGLAS R. GALASKO, MD
*University of California,
San Diego
La Jolla, CA*

ELKAN GAMZU, PhD
*enERGenetics
Newton, MA*

JACK GAULDIE, PhD
*McMaster University
Hamilton, Ontario
Canada*

DAVID S. GELDMACHER, MD
*Case Western Reserve University
School of Medicine
Cleveland, OH*

GUNDA I. GEORG, PhD
*University of Kansas
Lawrence, KS*

EZIO GIACOBINI, MD, PhD
*Geneva University Hospitals
Switzerland*

ALISON M. GOATE, PhD
*Washington University
School of Medicine
St. Louis, MO*

MICHAEL GOLD, MD
*Johnson & Johnson
Pharmaceutical Research
& Development
Titusville, NJ*

PAUL E. GOLD, PhD
*University of Illinois at
Urbana-Champaign
Champaign, IL*

GUNNAR K. GOURAS, MD
*Weill Medical College of
Cornell University
New York, NY*

ILLANA GOZES, PhD
*Tel Aviv University
Tel Aviv, Israel*

BARRY D. GREENBERG, PhD
*AstraZeneca Pharmaceuticals
Willmington, DE*

MICHAEL GRUNDMAN, MD
*Elan Pharmaceuticals
San Diego, CA*

JOHN HARDY, PhD
*National Institute on Aging
Bethesda, MD*

MITCHELL HARMAN, MD, PhD
*Kronos Foundation
Phoenix, AZ*

JOSEPH A. HELPERN, PhD
*NYU School of Medicine
New York, NY*

OREST HURKO, MD
*Wyeth Research
Collegeville, PA*

MICHAEL HUTTON, PhD
*Mayo Clinic Jacksonville
Jacksonville, FL*

NADEEM ISHAQUE, PhD
*GE Corporate Research &
Development
Niskayuna, NY*

CLIFFORD JACK, MD
*Mayo Clinic College
of Medicine
Rochester, MN*

WILLIAM JAGUST, MD
*University of California,
Berkeley
Berkeley, CA*

JEFFREY KAYE, PhD
*Oregon Health &
Science University
Portland, OR*

JUDITH KELLEHER-ANDERSSON,
PHD
*Neuronascent, Inc.
Clarksville, MD*

ROBERT KISILEVSKY, MD, PhD
FRCP
*Queens University
Kingston, Ontario
Canada*

DAVID KNOPMAN, MD
*Mayo Clinic College
of Medicine
Rochester, MN*

AMOS KORCZYN, MD, MSc
*Tel Aviv University
Tel Aviv, Israel*

KENNETH KOSIK, MD
*Brigham and Women's Hospital
Boston, MA*

DORA M. KOVACS, PhD
*Massachusetts General Hospital
Charlestown, MA*

ALAN P. KOZIKOWSKI, PhD
*Acenta
Arlington, VA*

ARTHUR F. KRAMER, PhD
*University of Illinois
Urbana, IL*

LEWIS H. KULLER, PhD
*University of Pittsburgh
Medical Center
Pittsburgh, PA*

FRANK M. LaFERLA, PhD
*University of California, Irvine
Irvine, CA*

DEBOMOY LAHIRI, PhD
*Indiana University
School of Medicine
Indianapolis, IN*

GARY LANDRETH, PhD
*Case Western Reserve University
School of Medicine
Cleveland, OH*

LIT-FUI LAU, PhD
*Pfizer Inc.
Groton, CT*

VIRGINIA M. Y. LEE, PhD
*University of Pennsylvania
Philadelphia, PA*

FRANK M. LONGO, MD, PhD
*University of North Carolina
School of Medicine
Chapel Hill, NC*

REBEKAH LOY, PhD
*University of Rochester
Rochester, NY*

ECKHARD MANDELKOW, PhD
*Max-Planck-Unit for
Structural Molecular Biology
Hamburg, Germany*

EVA-MARIA MANDELKOW, MD, PhD
*Max-Planck-Unit for
Structural Molecular Biology
Hamburg, Germany*

CHARLES J. MANLY, PhD
*Neurogen Corporation
Branford, CT*

ELIEZER MASLIAH, PhD
*University of California,
San Diego
La Jolla, CA*

DOUG MATTHEWS, PhD
*University of Memphis
Memphis, TN*

PATRICK C. MAY, PhD
*Eli Lilly and Company
Indianapolis, IN*

RICHARD MAYEUX, MD, MSc
*Columbia University
New York, NY*

BRUCE S. MCEWEN, PhD
*The Rockefeller University
New York, NY*

JAMES L. MCGAUGH, PhD
*University of California, Irvine
Irvine, CA*

ELIAS K. MICHAELIS, MD, PhD
*University of Kansas
Lawrence, KS*

MARY L. MICHAELIS, PhD
*University of Kansas
Lawrence, KS*

MYRON MILLER, MD
*Sinai Hospital of Baltimore
Baltimore, MD*

HANS JOERG MOEBIUS, PhD
*Merz and Company
Germany*

RICHARD MOHS, PhD
*Lilly Research Laboratories
Indianapolis, IN*

PERRY B. MOLINOFF, MD
*University of Pennsylvania
Philadelphia, PA*

DAVE MORGAN, PhD
*University of South Florida
Tampa, FL*

JOHN C. MORRIS, MD
*Washington University
School of Medicine
St. Louis, MO*

DAVID T. NASH, MD
*NIA-NNA
Bethesda, MD*

ALAN W. O'CONNELL, PhD
*Seroba Bioventures
Ireland*

BURTON ORLANDO, RPh
*Oxford Health Plus
Trumbull, CT*

GEORGE PERRY, PhD
*Case Western Reserve University
School of Medicine
Cleveland, OH*

SUZANA PETANCESKA, PhD
*NIA-NNA
Bethesda, MD*

RONALD C. PETERSEN, MD, PhD
*Mayo Clinic College
of Medicine
Rochester, MN*

WILLIAM POTTER, MD, PhD
*Lilly Research Laboratories
Indianapolis, IN*

DONALD L. PRICE, MD
*Johns Hopkins University
Baltimore, MD*

RAM RAMABHADRAN, PhD
*Environmental
Protection Agency
Research Triangle Park, NC*

G. WILLIAM REBECK, PhD
*Georgetown University
School of Medicine
Washington, DC*

GEORGE W. REBOK, PhD
*Johns Hopkins University
Baltimore, MD*

LORENZO REFOLO, PhD
*NINDS
Rockville, MD*

ERIC REIMAN, MD
*Banner Good Samaritan
Medical Center
Phoenix, AZ*

PETER B. REINER, VMD, PhD
*University of British
Columbia Hospital
Vancouver, BC
Canada*

NIKOLAOS K. ROBAKIS, PhD
*Mount Sinai School of
Medicine
Bronx, NY*

JACK T. ROGERS, PhD
*Massachusetts General Hospital
Charlestown, MA*

JOSEPH ROGERS, PhD
*Sun Health Research Institute
Sun City, AZ*

MARTIN ROSSOR, MD
*National Hospital for
Neurology and Neurosurgery
London, England*

BARBARA SAHAGAN, PhD
*Pfizer Inc.
Groton, CT*

STEPHEN SALLOWAY, MD
*Butler Hospital
Providence, RI*

KUMAR SAMBAMURTI, PhD
*Medical University of
South Carolina
Charleston, SC*

PHILIP SCHELTENS, PhD
*VU University Medical Center
Amsterdam, The Netherlands*

ALEXANDER SCRIABINE, MD
*Yale University Medical School
New Haven, CT*

KENNETH SELZER, MD, PhD
*NIA-NNA
Bethesda, MD*

EINAR M. SIGURDSSON, PhD
*NYU School of Medicine
New York, NY*

ISRAEL SILMAN, PhD
*The Weizmann
Institute of Science
Rehovot, Israel*

ELY SIMON, MD
*NeuroTrax Corporation
Bayside, NY*

SCOTT A. SMALL, MD
*Columbia University
New York, NY*

GARY W. SMALL, MD
*UCLA Neuropsychiatric
Institute
Los Angeles, CA*

JONATHAN D. SMITH, PhD
*The Cleveland Clinic Foundation
Cleveland, OH*

REISA SPERLING, MD
*Harvard Medical School
Belmont, MA*

ROSS L. STEIN, PhD
*Brigham and Women's Hospital
Boston, MA*

YAAKOV STERN, PhD
*Columbia University
New York, NY*

JOEL L. SUSSMAN, PhD
*The Weizmann Institute
of Science
Rehovot, Israel*

WALTER SZAREK, PhD
*Queens University
Kingston, Ontario
Canada*

JORDAN TANG, PhD
*Oklahoma Medical
Research Foundation
Oklahoma City, OK*

RUDOLPH E. TANZI, PhD
*Massachusetts General Hospital
Charlestown, MA*

PIERRE TARIOT, MD
*University of Rochester
Rochester, NY*

TINA L. TEKIRIAN, PhD
*The National Cancer Institute
Frederick, MD*

ANDREA J. TENNER, PhD
*University of California, Irvine
Irvine, CA*

LEON J. THAL, MD
*University of California,
San Diego
La Jolla, CA*

JOHN TROJANOWSKI, MD, PhD
*University of Pennsylvania
Philadelphia, PA*

TIM TULLY, PhD
*Helicon Therapeutics
Cold Spring Harbor, NY*

MARK H. TUSZYNSKI, MD
*University of California,
San Diego
La Jolla, CA*

AXEL UNTERBECK, PhD
*Oxford Bioscience Partners
Boston, MA*

LINDA VAN ELDIK, PhD
*Northwestern University
Medical School
Chicago, IL*

NICOLAAS VERHOEFF, MD, PhD
*University of Toronto
Toronto, Ontario
Canada*

ANABELLA VILLALOBOS, PhD
*Pfizer Inc.
Groton, CT*

TOM VON STERNBERG, MD
*HealthPartners
Minneapolis, MN*

MICHAEL W. WEINER, MD
*University of California,
San Diego
La Jolla, CA*

HAREL WEINSTEIN, PhD
*Weill Medical College of
Cornell University
New York, NY*

MARTA WEINSTOCK-ROSIN, PhD
*Hebrew University
Medical Centre
Jerusalem, Israel*

PETER WHITEHOUSE, MD, PhD
*Case Western Reserve University
School of Medicine
Cleveland, OH*

DAVID WILSON, PhD
*Brigham and Women's Hospital
Boston, MA*

MANFRED WINDISCH, PhD
*JSW-Research
Forschungslabor GmbH
Graz, Austria*

THOMAS WISNIEWSKI, MD
*NYU School of Medicine
New York, NY*

MICHAEL W. WOLFE, PhD
*Brigham and
Women's Hospital
Boston, MA*

TONY WYSS-CORAY, PhD
*Stanford University
Stanford, CA*

AUSTIN YANG, PhD
*University of Southern
California
Los Angeles, CA*

MOUSA B.H. YODIM, PhD
*Technion
Haifa, Israel*

•••

BUSINESS ADVISORY BOARD

JOHN K. CLARKE
*Cardinal Partners
Princeton, NJ*

MARK A. COCHRAN, PhD
*NeuroVentures Capital, LLC
Charlottesville, VA*

MATTHEW S. CRAWFORD
*Cockrell Interests, Inc.
Houston, TX*

BARBARA J. DALTON, PhD
*EuclidSR Partners
New York, NY*

STEVEN G. DICKMAN
*CBT Advisors
Cambridge, MA*

JEFF DOBRO, MD
*Creative Medical
Management, Inc.
Boonton Twp., NJ*

JULIE ESKAY-EAGLE
*September Ventures LLC
Cos Cob, CT*

STEPHEN M. GOLDBERG, PhD
*The Channel Group
New York, NY*

STEPHEN M. GOODMAN, ESQ.
*Pryor Cashman Sherman
& Flynn, LLP
New York, NY*

ELAINE JONES, PhD
*EuclidSR Partners
New York, NY*

PERRY KARSEN
*Celgene Corporation
Summit, NJ*

GLENN J. KLINE
*Academy Funds
Research Triangle Park, NC*

LARRY KUNSTADT, PhD
*vFinance Investments, Inc.
New York, NY*

EMER LEAHY, PhD
*Psychogenics Inc.
Hawthorne, NY*

MICHAEL LYTTON, PhD
*Oxford Bioscience Partners
Boston, MA*

ROBERT G. NAGRO
*ITF Global Partners
New York, NY*

DANIEL J. O'CONNELL
*NeuroVentures Capital, LLC
Charlottesville, VA*

WILLIAM PAIVA
*Chisholm Private Capital
Tulsa, OK*

LYNNE H. PARKER, PhD
*Trillium Medical
Ventures, LLC
New York, NY*

DEBRA PEATTIE, PhD
*Valeo Medical Inc.
Concord, MA*

CATHRIN PETTY
*Apax Partners & Co.
London, England*

RANA QURASHI, PhD
*Standard & Poors
New York, NY*

CHERYL V. REICIN, PhD
*Torys
Toronto, Ontario
Canada*

DAVID W. SUMMA
*Acumen Pharmaceuticals, Inc.
Glenview, IL*

JOHN TALLMAN
*Helicon Therapeutics
Cold Spring Harbor, NY*

DOUG A. ZINGALE
*Greenberg Traurig, LLP
Boston, MA*

•••

FUNDDED PROGRAMS

Drug Discovery

OTTAVIO ARANCIO, MD, PhD
Nathan Kline Institute
Orangeburg, NY
*Calpains: A Treatment of
Alzheimer's Disease*
Award: \$121,126
Duration: 2000 – 2001

Columbia University
New York, NY
*Calpain Inhibitor: A Treatment
of Alzheimer's Disease - Part 2*
Award: \$88,205
Duration: 2003 – 2005

ETIENNE-EMILE BAULIEU, PhD
MAPREG
Le Kremlin-Bicetre
Cedex France
*Control of Microtubule
Assembly in the Nervous
System: Novel Approach for the
Prevention and Treatment of
Neurodegenerative Diseases*
Award: \$150,000
Duration: 2002 – 2003

JOSEPH K. BELANOFF, MD
Corcept Therapeutics, Inc.
Menlo Park, CA
*Slowing the Progression
of Cognitive Decline in
Alzheimer's Disease Using
Mifepristone*
Award: \$462,929
Duration: 2001 – 2003

DALE E. BREDESEN, PhD
Buck Institute for
Age Research
Novato, CA
*Development of Drugs for a
New Therapeutic Target in
Alzheimer's Disease*
Award: \$100,000
Duration: 2002 – 2003

*Screening for Alzheimer's
Therapeutics Based on a
Novel Target*
Award: \$100,000
Duration: 2004

ROBERTA DIAZ BRINTON, PhD
University of Southern
California
Los Angeles, CA
*Allopregnanolone as a
Neurogenic Factor for
Recovery of Neurons in
Alzheimer's Disease*
Award: \$122,661
Duration: 2005 – 2006

JERRY BUCCAFUSCO, PhD
Prime Behavior Testing
Laboratories, Inc.
Augusta, GA
*A Computer-Assisted Cognitive
Test Battery for Aged Monkey*
Award: \$112,947
Duration: 2001 – 2003

*Novel Properties of Analogs of
Choline for the Treatment of
Neurodegenerative Diseases*
Award: \$259,651
Duration: 2003 – 2005

LUC BUEE, PhD
INSERM U422 (French
National Institute for Health
and Medical Research)
Lille, France
*Towards Pin1 Inhibitors
in the Treatment of
Alzheimer's Disease*
Award: \$85,000
Duration: 2003 – 2004

ANNE CATALDO, PhD
McLean Hospital/Harvard
Medical School
Belmont, MA
*A Novel Method of Cell-
Mediated Therapy for
Alzheimer's Disease*
Award: \$75,000
Duration: 2005 – 2006

SIEW YEEN CHAI, PHD
Howard Florey Institute
Australia
IRAP - Novel Target for the Development of Memory-Enhancing Agents
Award: \$82,000
Duration: 2005 – 2006

CHRISTOPHER B. ECKMAN, PHD
Mayo Clinic Jacksonville
Jacksonville, FL
Herbal Extracts that Reduce A-Beta Peptide Accumulation
Award: \$127,567
Duration: 2001 – 2002
Natural Product Extracts that Reduce A-Beta Peptide Accumulation
Award: \$250,000
Duration: 2002 – 2004

ALAN FADEN, MD
Georgetown University
School of Medicine
Washington, DC
Modulation of Beta-Amyloid Induced Neuronal Apoptosis by Selective Activation of Metabotropic Glutamate Receptors
Award: \$100,000
Duration: 2001 – 2005

AVRAHAM FISHER, PHD
Israel Institute for Biological Research
Ness-Ziona, Israel
Novel M1 Muscarinic Agonists: From Treatment Toward Delaying Progression of Alzheimer's Disease
Award: \$450,000
Duration: 1999 – 2002

ILLANA GOZES, PHD
Tel Aviv University
Tel Aviv, Israel
Israel Femtomolar-Acting Neuroprotective Peptides: Application for Inhibition of Neurodegenerative Disease
Award: \$220,000
Duration: 1999 – 2001

Allon Therapeutics, Inc.
Vancouver, BC
Canada
Alzheimer's Disease Biotech Program
Award: \$253,100
Duration: 2002 – 2003

MICHAEL HUTTON, PHD
Mayo Clinic Jacksonville
Jacksonville, FL
In Vivo Testing of Compounds that Block the Development of Neurofibrillary Tau Pathology
Award: \$196,662
Duration: 2004 – 2006

KHALID IQBAL, PHD
NY State Institute for Basic Research in Developmental Disabilities
New York, NY
Screening Assays to Inhibit Alzheimer Neurofibrillary Degeneration
Award: \$528,869
Duration: 2000 – 2004

LEE-WAY JIN, MD, PHD
University of Washington
Seattle, WA
The Amelioration of A-Beta Aggregation and Cell Toxicity by Tricyclic Pyrone Compounds
Award: \$50,000
Duration: 2000 – 2001

JUNE KINOSHITA
Alzheimer Research Forum Foundation
Waltham, MA
Alzheimer Cheminformatics Resource
Award: \$60,275
Duration: 2004 – 2006

ROBERT KISILEVSKY, MD, PHD
FRCPC Queens University
Kingston, Ontario
Canada
Novel Glycosaminoglycan Precursors As Anti-Amyloid Agents
Award: \$245,300
Duration: 2000 – 2003
Novel Glycosaminoglycan (GAG) Precursors as Anti-Amyloid Agents - Part 2
Award: \$191,220
Duration: 2003 – 2004

KENNETH KOSIK, MD
Brigham and Women's Hospital
Boston, MA
Identifying Drugs that Inhibit Kinase-Induced Dissociation of Tau from Microtubules
Award: \$130,000
Duration: 2001 – 2002
The Development of CDK5 Inhibitors
Award: \$199,000
Duration: 2004 – 2005

DORA M. KOVACS, PHD
Massachusetts General Hospital
Charlestown, MA
Effect of ACAT Inhibition on A-Beta Levels in PS1-APP Transgenic Mice
Award: \$125,000
Duration: 2002 – 2004

GRANT A. KRAFFT, PHD
Acumen Pharmaceuticals, Inc.
Glenview, IL
High Throughput Screens for ADDL-Blocker Compounds
Award: \$133,493
Duration: 2003 – 2004

DANIEL LASKOWITZ, PHD
Duke University Medical Center
Durham, NC
The Effect of ApoE Mimetic Therapeutic Peptide in a Murine Model of AD.
Award: \$102,364
Duration: 2004 – 2005
An ApoE-Derived Therapeutic Improves AD Pathology in a Murine Model following Head Injury - Year 2
Award: \$93,449
Duration: 2005 – 2006

SEBASTIAN LAZARENO, PHD
Medical Research Council Technology
London, England
Development of Selective Allosteric Enhancers at Human Muscarinic Receptors
Award: \$473,626
Duration: 2001 – 2003

EDWARD D. LEVIN, PHD
Duke University Medical Center
Durham, NC
EC-SOD Protection from Aging-Induced Cognitive Deficits Due to Oxidative Stress
Award: \$52,775
Duration: 2003 – 2004

STUART A. LIPTON, PHD
Neuromolecular, Inc.
Mill Valley, CA
Drug Development Plan for Nitro-Memantine (Memantine-ONO 2) Derivatives
Award: \$244,700
Duration: 2004 – 2006

FRANK M. LONGO, MD, PHD
University of North Carolina
School of Medicine
Chapel Hill, NC
Alzheimer's Therapeutics: Neurotrophin Small Molecule Mimetics
Award: \$521,517
Duration: 2000 – 2004
BDNF Small Molecule Mimetics
Award: \$162,500
Duration: 2004 – 2005
NGF Small Molecule Mimetics: Preclinical Studies
Award: \$150,000
Duration: 2005 – 2006

REBEKAH LOY, PHD
University of Rochester
Rochester, NY
Valproate and Lithium to Inhibit Tau Pathophysiology
Award: \$115,309
Duration: 2002 – 2004

ECKHARD MANDELKOW, PHD
Max-Planck-Unit for Structural Molecular Biology
Hamburg, Germany
Search for Inhibitors of Tau Aggregation
Award: \$156,000
Duration: 2003 – 2004
Search for Inhibitors of Tau Aggregation
Award: \$159,500
Duration: 2005 – 2006

MARCOS A. MARQUES, PHD
ApoLogic, Inc.
Cincinnati, OH
Novel Drug Target in Alzheimer's Disease
Award: \$145,395
Duration: 2002 – 2003

YASUJI MATSUOKA, PHD
Georgetown University
Medical Center
Washington, DC
Development of Abeta-Binding Agents for Abeta Sequestration Therapy
Award: \$98,500
Duration: 2003 – 2004

SIMON MELOV, PHD
Buck Institute for Age Research
Novato, CA
Potential Therapeutics for Alzheimer's Disease
Award: \$97,987
Duration: 2001 – 2004

- WILLIAM S. MESSER, JR., PhD
University of Toledo
Toledo, OH
Development of Selective Muscarinic Agonists for the Treatment of Alzheimer's Disease
Award: \$267,066
Duration: 2000 – 2001
- MARY L. MICHAELIS, PhD
University of Kansas
Lawrence, KS
Microtubule - Stabilizing Drugs for Alzheimer's Disease
Award: \$300,248
Duration: 1999 – 2003
In Vivo Analysis of Effects of Microtubule-Stabilizing Drugs in Tau Mutant Mice
Award: \$258,352
Duration: 2003 – 2006
- SUZANA PETANCESKA, PhD
Nathan Kline Institute
Orangeburg, NY
Pharmacogenetic Effects of Human apoE on the Amyloid-Reducing Activity of Cholesterol Lowering Drugs in a Transgenic Mouse Model for Alzheimer's Disease
Award: \$360,742
Duration: 2000 – 2003
Efficacy of Oral Heparin Treatment for Alzheimer's Disease
Award: \$98,563
Duration: 2003 – 2004
- LEONARD PETRUCCELLI, PhD
Mayo Clinic Jacksonville
Jacksonville, FL
Hsp70 Activity and Tau A Therapeutic Target
Award: \$125,000
Duration: 2004 – 2005
- RAM RAMABHADHRAN, PhD
Tranzyme Pharma, Inc.
Research Triangle Park, NC
Cell Culture Models and Animal Models of Alzheimer's Disease
Award: \$493,550
Duration: 2003 – 2005
- CIARAN M. REGAN, PH.D., DSC
University College Dublin
Belfield, Dublin
Ireland
Determination of the Effect of Chronic Administration of ABS-205 on Morris Water Maze Learning in the Aged Rat
Award: \$50,000
Duration: 2000
- PETER B. REINER, VMD, PhD
Active Pass Pharmaceuticals
Vancouver, BC
Canada
Brain-Expressed ABC Transporters as Targets for AD Therapeutics
Award: \$150,000
Duration: 2000 – 2001
- ELLIOTT RICHELSON, MD
Mayo Clinic Jacksonville
Jacksonville, FL
Peptide Nucleic Acids Targeted to the Amyloid Precursor Protein
Award: \$200,000
Duration: 2001 – 2003
- JACK T. ROGERS, PhD
Massachusetts General Hospital
Charlestown, MA
A New Translational Regulatory Target in the Alzheimer's APP Transcript
Award: \$100,000
Duration: 2000 – 2002
Alzheimer's Disease Drug Discovery Targeted to the APP-mRNA 5' Untranslated Region
Award: \$96,734
Duration: 2001 – 2003
Small Molecule Drug Discovery Targeted To The Alzheimer's APP-mRNA 5' Untranslated Region
Award: \$100,000
Duration: 2003 – 2005
- KUMAR SAMBAMURTI, PhD
Medical University of South Carolina
Charleston, SC
Evaluation of GPI-Anchored Proteins as Targets for Inhibition of Beta-Secretase
Award: \$200,000
Duration: 2000 – 2002
- STEVEN SCHREIBER, MD
University of California, Irvine
Irvine, CA
Efficacy of the Histone Deacetylase Inhibitor, SAHA, in AD Transgenic Mice- A Proof-of-Concept Study
Award: \$130,000
Duration: 2006 – 2007
- MICHAEL L. SHELANSKI, MD, PhD
Columbia University
New York, NY
Pharmacological Reversal of the Behavioral and Electrical Sequelae of A-Beta Deposition
Award: \$50,000
Duration: 2004 – 2005
- JONATHAN D. SMITH, PhD
The Cleveland Clinic
Foundation
Cleveland, OH
Estrogen and ApoE; Interaction and Effect on Pathogenesis in a Mouse Model of Alzheimer's Disease
Award: \$416,130
Duration: 1999 – 2002
Drug Discovery: Estrogen Related Compounds in Mouse Models of Alzheimer's Disease
Award: \$90,000
Duration: 2003 – 2004
- BEKA SOLOMON, PhD
Tel Aviv University
Tel Aviv, Israel
A Novel Approach Towards Vaccination Against Alzheimer Beta-Amyloid Peptide
Award: \$100,000
Duration: 2002 – 2004
- WOLFGANG J. STREIT, PhD
University of Florida
Gainesville, FL
Role of Fractalkine in Regulating Neuronmicroglia Interactions
Award: \$126,492
Duration: 2003 – 2005
- SIDNEY STRICKLAND, PhD
The Rockefeller University
New York, NY
Analysis of the Role to tPA and Plasminogen in Alzheimer's Disease
Award: \$256,480
Duration: 2001 – 2003
- STEPHEN M. STRITTMATER, PhD
Yale University Medical School
New Haven, CT
Nogo Antagonists in Axon Regeneration and Plasticity
Award: \$267,928
Duration: 2001 – 2003
- JOEL L. SUSSMAN, PhD
The Weizmann Institute
of Science
Rehovot, Israel
Structural and Functional Analysis of Beta Secretase as a Potential Target for Therapeutic Intervention in Alzheimer's Disease
Award: \$312,555
Duration: 2002 – 2005
- JORDAN TANG, PhD
Zapaq, Inc.
Oklahoma City, OK
Studies on Human Memapsin (Beta-Secretase): Prerequisite of Drug Design for Alzheimer's Disease
Award: \$500,000
Duration: 2002 – 2003
Founders Program: Studies on Human Memapsin 2 (Beta-Secretase): Drug Design for Alzheimer's Disease
Award: \$250,000
Duration: 2002 – 2004
- RUDOLPH E. TANZI, PhD
Massachusetts
General Hospital
Charlestown, MA
Small Molecule Therapeutics for Alzheimer's Disease
Award: \$340,000
Duration: 2001 – 2004
- GREG R. J. THATCHER, PhD
University of Illinois, Chicago
Chicago, IL
Generation and Optimization of NO Mimetics for Treatment of Alzheimer's Disease
Award: \$150,000
Duration: 2004 – 2005
Generation and Optimization of NO mimetics for Treatment of Alzheimer's Disease - Part 2
Award: \$130,000
Duration: 2006 – 2007
- TIM TULLY, PhD
Helicon Therapeutics
Cold Spring Harbor, NY
CREB and the Discovery of Cognitive Enhancers
Award: \$238,780
Duration: 2001 – 2002
- DUANE L. VENTON, PhD
University of Illinois, Chicago
Chicago, IL
A Combinatorial Search for Beta-Cyclodextrins to Abate the Neurotoxicity of Amyloid-Beta-Peptide in Alzheimer's Disease
Award: \$311,916
Duration: 2001 – 2004

D. MARTIN WATTERSON, PhD
Northwestern University
Medical School
Chicago, IL
*Ligands that Suppress
Neuroinflammatory Responses*
Award: \$476,278
Duration: 2001 – 2004

*Novel Therapeutics Targeting
Neuroinflammation*
Award: \$140,000
Duration: 2005 – 2006

NICHOLAS WEBSTER, PhD
Veteran's Medical Research
Foundation
San Diego, CA
*Development of Cell-Permeable
NGF Mimetics*
Award: \$130,000
Duration: 2006 – 2007

MARTA WEINSTOCK-ROSIN, PhD
Hebrew University
Medical Centre
Jerusalem, Israel
*Award for Major Scientific
Achievement in Drug
Discovery and Development for
Alzheimer's Disease*
Award: \$100,000
Duration: 2004 – 2005

MANFRED WINDISCH, PhD
JSW-Research
Forschungslabor GmbH
Graz, Austria
*Development of a New
Treatment for Alzheimer's
Disease and Parkinson's Disease
using Anti-Aggregatory Beta-
Synuclein Derived Peptides*
Award: \$260,000
Duration: 2002 – 2004

MICHAEL W. WOLFE, PhD
Brigham and
Women's Hospital
Boston, MA
*Helical Peptidomimetics as
Inhibitors of Alzheimer's
Gamma-Secretase*
Award: \$147,067
Duration: 2000 – 2002

TONY WYSS-CORAY, PhD
Stanford University
Stanford, CA
*The TGF-Beta Pathway as a
Therapeutic Target to Treat
Alzheimer's Disease*
Award: \$152,232
Duration: 2003 – 2004

*The TGF-Beta Pathway as a
Therapeutic Target to Treat
Alzheimer's Disease*
Award: \$152,300
Duration: 2004 – 2005

MING-MING ZHOU, PhD
Mount Sinai Medical Center
Rochester, NY
*Structure-based Functional
Design of Antagonists for
Glutamate Receptors*
Award: \$600,621
Duration: 2000 – 2004

BERISLAV ZLOKOVIC, MD, PhD
University of Rochester
Rochester, NY
*Blockers of RAGE/Amyloid-
Beta Interaction at the Blood
Brain Barrier*
Award: \$165,723
Duration: 2004 – 2005

*Blockers of RAGE/Amyloid-
Beta Interaction at the Blood
Brain Barrier*
Award: \$130,000
Duration: 2006 – 2007

•••

F U N D E D P R O G R A M S

C l i n i c a l

DANIEL G. CHAIN, PhD
Mindset BioPharmaceuticals
(USA) Inc.
New York, NY
*Drug Development for AD:
Development of New
Antioxidants*
Award: \$524,018
Duration: 2000 – 2002

CARL W. COTMAN, PhD
University of California, Irvine
Irvine, CA
*Phase I Pilot Study
of Combination
Antioxidants in Aging*
Award: \$100,000
Duration: 2002 – 2003

SUZANNE CRAFT, PhD
Seattle Institute for
Biomedical and Clinical
Research (SIBCR)
Seattle, WA
*Intranasal Insulin
Administration and
Memory in AD*
Award: \$181,516
Duration: 2003 – 2006

JOHN F. DEBERNARDIS, PhD
Molecular Geriatrics
Corporation
Vernon Hill, IL
*Novel Therapeutic Screening
Technology for Alzheimer's
Disease*
Award: \$51,470
Duration: 2000 – 2001

CHARLES S. DECARLI, MD
University of California, Davis
Sacramento, CA
*Clinical Interpretation of
MRI to Predict Conversion
of Mild Cognitive Impairment
to Dementia*
Award: \$35,000
Duration: 2003 – 2004

STEVEN A. JOHNSON, PhD
Cortex Pharmaceuticals, Inc.
Irvine, CA
*Randomized, Double-Blind
Clinical Study of Ampalex
(CX516) in Patients with
Mild Cognitive Impairment*
Award: \$247,300
Duration: 2000 – 2002

MEI-PING KUNG, PhD
University of Pennsylvania
Philadelphia, PA
*Inhibitors of Beta Amyloid
Aggregates: Characterization of
Radio-odinated Ligands for
Beta-Amyloids*
Award: \$263,521
Duration: 2000 – 2002

*Evaluation of Anti-Plaque
Treatment for
Alzheimer's Disease*
Award: \$90,000
Duration: 2003 – 2004

BRUCE L. MILLER, MD
UCLA Memory and
Aging Center
Los Angeles, CA
*UCSF Investigation of the
Effects of Testosterone on
Cognition in Male Patients
with Mild Alzheimer's Disease*
Award: \$150,000
Duration: 2003 – 2004

PETER J. NEUMANN, DSC
Harvard School of
Public Health
Boston, MA
*Public Attitudes Towards
Genetic Testing in
Alzheimer's Disease*
Award: \$77,072
Duration: 2001

JOHN M. RINGMAN, MD
UCLA School of Medicine
Los Angeles, CA
*A Phase II, Double-Blind,
Placebo-Controlled Study of the
Safety and Tolerability of Three
Doses of Curcumin Versus
Placebo in Patients with Mild
to Moderate Alzheimer's Disease*
Award: \$299,451
Duration: 2003 – 2006

MARY SANO, PhD
Mount Sinai Medical Center
New York, NY
*Effect of High-Dose
Supplements on Blood
Homocysteine in
Alzheimer's Disease*
Award: \$178,801
Duration: 2000 – 2001

BARBARA B. SHERWIN, PhD
McGill University
Verdun, Quebec
Canada
*Effects of Estradiol on Cognitive
Function in Elderly Men with
Mild Cognitive Impairment*
Award: \$186,000
Duration: 1999 – 2004

ELY SIMON, MD
NeuroTrax Corporation
Bayside, NY
*Mindstreams Cognitive Testing
for Early Diagnosis and
Longitudinal Follow-up of
Dementia: A 3-Center
Validation Study*
Award: \$319,711
Duration: 2003 – 2006

D. LARRY SPARKS, PhD
Sun Health Research Institute
Sun City, AZ
*A Phase II Trial Investigating
the Effect of the HMG-CoA
Reductase Inhibitor
Atorvastatin Calcium (Lipitor)
in the Treatment of
Alzheimer's Disease*
Award: \$450,000
Duration: 2000 – 2003

MARK H. TUSZYNSKI, MD
University of California,
San Diego
La Jolla, CA
*A Phase I Study of Nerve
Growth Factor Ex Vivo Gene
Therapy for Alzheimer's Disease*
Award: \$402,113
Duration: 2000 – 2003

JOHN B. ZABRISKIE, MD
The Rockefeller University
New York, NY
*Is Variation in the Production
of TNF - In Elderly Pre-
Operative Patients Predictive
of Post-Operative Cognitive
Complications*
Award: \$86,335
Duration: 1999 – 2000

JUN TAN, PhD
University of South Florida
Tampa, FL
*Green Tea Epigallocatechin-3-
Gallate (EGCG) Modulates
Amyloid Precursor Protein
Cleavage and Reduces
Amyloidosis in Alzheimer's
Transgenic Mice*
Award: \$74,810
Duration: 2005 – 2006

MARC E. WEKSLER, PhD
Weill Medical College of
Cornell University
New York, NY
*Human Anti-A Beta
Antibodies for the Treatment
of Alzheimer's Disease*
Award: \$80,210
Duration: 2002

•••

FUND E D P R O G R A M S

P r e v e n t i o n

JOHN P. BLASS, MD, PhD
Burke Medical
Research Institute
White Plains, NY
Nutritional Treatment for AD
Award: \$100,250
Duration: 1999 – 2000

ARTHUR F. KRAMER, PhD
University of Illinois
Urbana, IL
*Influence of Fitness on the
Neurodegenerative Function
of Older Adults*
Award: \$433,054
Duration: 2001 – 2004

THOMAS T. PERLS, MD
Boston University School
of Medicine
Boston, MA
*Identifying Genes Predisposing
to Successful Cognitive Aging*
Award: \$522,132
Duration: 1999 – 2002

*Enhancing Cognitive and Brain
Function of Older Adults
Through Fitness Training*
Award: \$100,000
Duration: 2005 – 2006

•••

FUND E D P R O G R A M S

E a r l y D e t e c t i o n

JEFFREY L. CUMMINGS, MD
UCLA School of Medicine
Los Angeles, CA
*Multicenter Analysis of
Hippocampal Morphology
in MCI*
Award: \$300,000
Duration: 2000 – 2002

ROBERT P. FRIEDLAND, MD
Case Western Reserve
University School of Medicine
Cleveland, OH
*Genetic and Environmental
Risk Factors for Alzheimer's
Disease in Israeli Arabs*
Award: \$50,000
Duration: 1999 – 2000

MARK A. GLUCK, PhD
Rutgers University - Newark
Newark, NJ
*Novel Behavioral Screening
Tools for Memory Assessment in
Rodents and Humans*
Award: \$45,000
Duration: 2005 – 2006

DAVID KNOPMAN, MD
Mayo Clinic College
of Medicine
Rochester, MN
*Telephonic Screening for
Cognitive Impairment*
Award: \$5,828
Duration: 2000

MONY DELEON, EdD
NYU School of Medicine
New York, NY
*MRI and CSF Tau Protein
Levels: An Early Screening Test
for Alzheimer's Disease*
Award: \$85,000
Duration: 1999 – 2001

*Genetic and Environmental
Risk Factors for Alzheimer's
Disease in Israeli Arabs (Part 2)*
Award: \$210,000
Duration: 2000 – 2003

JOSEPH A. HELPERN, PhD
NYU School of Medicine
New York, NY
*High Field (3T) MRI
Assessment of the Biophysical
Environment of the
Alzheimer's Brain*
Award: \$150,000
Duration: 2003 – 2005

PHILIP SCHELTENS, PHD
 VU University
 Medical Center
 Amsterdam, The Netherlands
Functional Connectivity in Elderly Controls and Alzheimer's Patients Using Resting State fMRI: A Pilot Study
 Award: \$85,550
 Duration: 2003 – 2004

GARY W. SMALL, MD
 UCLA Neuropsychiatric Institute
 Los Angeles, CA
FDDNP-PET Imaging for Early Detection of Alzheimer's Disease
 Award: \$200,000
 Duration: 2000 – 2003

SCOTT A. SMALL, MD
 Columbia University
 New York, NY
Imaging Mouse Models of Alzheimer's Disease
 Award: \$92,733
 Duration: 2003 – 2004

D. LARRY SPARKS, PHD
 Sun Health Research Institute
 Sun City, AZ
Is Elevated Serum Cholesterol Predictive of Developing AD?
 Award: \$346,372
 Duration: 2001 – 2006

LEON J. THAL, MD
 University of California,
 San Diego
 La Jolla, CA
Utility of MRI to Predict Progression from MCI to AD and Treatment Response to Vitamin E and Donepezil
 Award: \$399,890
 Duration: 1999 – 2004

YANMING WANG, PHD
 University of Illinois, Chicago
 Chicago, IL
Amyloid Probes in Aging and Alzheimer's Disease: Dual Agents for Both PET and SPECT
 Award: \$197,000
 Duration: 2001 – 2005

MOUSA B.H. YODIM, PHD
 Technion
 Haifa, Israel
Development and Molecular Mechanism of Neuroprotective Activity of Novel Bifunctional Cholinesterase-monoamine Oxidase Inhibitor-iron Chelators for the Treatment of Alzheimer's Disease and Lewy Body Disease
 Award: \$75,000
 Duration: 2005 – 2006

•••

ADDF / ISOA PARTNERSHIP PROGRAMS

ALZHEIMER'S RESEARCH CONSORTIUM (ARC)
New Animal Models for Alzheimer's Disease
 Award: \$200,000
 Duration: 2003 – 2005

ALZHEIMER'S RESEARCH CONSORTIUM (ARC)
Emory: Transgenic Rat Model of Alzheimer's Disease
Harvard: Novel Fly and Mouse Models for the P25/CDK5 Kinase
 Award: \$100,000
 Duration: 2005 – 2006

ELAN PHARMACEUTICALS, INC.
 San Diego, CA
Novel Approaches to Drug Discovery for Alzheimer's Disease
 Award: \$500,000
 Duration: 2005 – 2008

NATIONAL INSTITUTE ON AGING
 Bethesda, MD
Partnership Grant between ISOA, NIA and NINDS: Grants for Alzheimer's Disease Drug Discovery
 Award: \$300,000
 Duration: 2005 – 2007

NIH ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE
 Award: \$100,000
 Duration: 2005

•••

FUNDED PROGRAMS

Grant Awarded Conferences

ROBERT N. BUTLER, MD
 International Longevity Center (ILC)
 New York, NY
The Aging Factor in Health and Disease: An Interdisciplinary Workshop for Scientists
 Award: \$9,000
 Duration: 1999

Biomarkers of Aging Workshop
 Award: \$10,000
 Duration: 2000

Workshop on Longevity Genes: From Primitive Organisms to Man
 Award: \$5,000
 Duration: 2001

Workshop on Andropause: Pros and Cons of Testosterone and its Effects on CNS
 Award: \$10,000
 Duration: 2002

The ILC-ISOA-Canyon Ranch Series on Cognitive Aging: Sleep Disorders
 Award: \$7,500
 Duration: 2002

Workshop on: Physical, Mental and Social Activities Affecting Cognitive Health
 Award: \$15,000
 Duration: 2003

Stress: Putting the Brain Back into Medicine
 Award: \$5,000
 Duration: 2004

JOYCE CHASE
 Yale University Medical School
 New Haven, CT
Cognition Enhancers, Anti-Alzheimer and Neuroprotective Drugs' Symposium
 Award: \$5,000
 Duration: 2000

AVRAHAM FISHER, PHD
 Israel Institute for Biological Research
 Ness-Ziona, Israel
The XIth International Symposium on Cholinergic Mechanisms - Function and Dysfunction
 Award: \$5,000
 Duration: 2001

ROBERT P. FRIEDLAND, MD
 Case Western Reserve University School of Medicine
 Cleveland, OH
International Symposium on Alzheimer's Disease in Middle East
 Award: \$20,000
 Duration: 2001

Regional Symposium on Alzheimer's Disease and Related Disorders in the Middle East
 Award: \$3,000
 Duration: 2005

EZIO GIACOBINI, MD, PhD
Geneva University Hospitals
Switzerland
*Seventh International
Geneva/Springfield Symposium
on Advances in
Alzheimer's Therapy*
Award: \$5,000
Duration: 2002

*8th International
Montreal/Springfield
Symposium on Advances in
Alzheimer's Therapy*
Award: \$5,000
Duration: 2003

Yael Goshen, PhD
The Alzheimer's Association
of Israel (AAI)
Ramar - Gan, Israel
*The First Israeli Consensus
Conference on the Issue of
The Treatment of Alzheimer
Patients in Israel*
Award: \$10,000
Duration: 2002

ILLANA GOZES, PhD
Tel Aviv University
Tel Aviv, Israel
*Summer Neuropeptide
2003 Conference*
Award: \$5,000
Duration: 2003

NAIM M. GRIBAA
The Jewish Home & Hospital
Lifecare System
New York, NY
Alzheimer's Conference
Award: \$2,500
Duration: 2003

ISRAEL HANIN, PhD
Loyola University Chicago
Maywood, IL
*Alzheimer's and Parkinson's
Disease: New Perspectives
6th International Conference*
Award: \$5,000
Duration: 2003

AMOS KORCZYN, MD, MSc
Tel Aviv University
Tel Aviv, Israel
*Second International Congress
On Vascular Dementia*
Award: \$5,000
Duration: 2002

*Third International Congress
on Vascular Dementia*
Award: \$5,000
Duration: 2003

JED A. LEVINE, MA
Alzheimer's Association
New York, NY
*Bi-Annual Research Seminar
Series on Alzheimer's Disease
and Related Disorders of the
Aging Nervous System for the
New York City Research Group*
Award: \$5,000
Duration: 2001

*Bi-Annual Research Seminar
Series on Alzheimer's Disease
and Related Disorders of the
Aging Nervous System for the
New York City Research Group*
Award: \$5,000
Duration: 2002

MARK P. MATTSON, PhD
National Institute on Aging
Gerontology Research Center
Baltimore, MD
*Successful Aging: 30th Annual
Meeting of the American Aging
Assoc., 15th Annual Meeting
of the American College of
Clinical Gerontology*
Award: \$4,000
Duration: 2001

RON C. PECK
Neurological Disease
Foundation
Burlingame, CA
*Challenging Views of
Alzheimer's Disease*
Award: \$2,500
Duration: 2005

JAMES F. TOOLE, PhD
Wake Forest Health Sciences
Winston-Salem, NC
*Planning for A Prospective,
Randomized Study for the
Prevention & Treatment of
Post-Stroke Dementia*
Award: \$7,500
Duration: 2002

ANDERS WALLIN, MD, PhD
Institute of Clinical
Neuroscience
Sweden
*The 1st Congress of the
International Society for
Vascular Behavioural and
Cognitive Disorders
(VAS-COG 2003)*
Award: \$5,000
Duration: 2003

MICHAEL W. WEINER, MD
Northern California
Institute for Research and
Education (NCIRE)
San Francisco, CA
*Neuroimaging of Alzheimer's
Disease and Related Disorders'
Satellite Meeting*
Award: \$5,000
Duration: 2000

MANFRED WINDISCH, PhD
JSW-Research
Forschungslabor GmbH
Graz, Austria
*5th International Conference on
Aging and Dementia - Current
and Future Concepts*
Award: \$5,000
Duration: 2001

•••

FUNDDED PROGRAMS

Partnership Sponsored Conferences

*Barriers to the Discovery
and Development of Drugs
for Alzheimer's Disease*
Duration: 2000

*Achieving Cognitive Vitality
with Aging*
Duration: 2000

*First Annual
Investigators' Meeting*
Duration: 2000

*Second Annual
Investigators' Meeting*
Duration: 2001

*Third Annual
Investigators' Meeting*
Duration: 2002

*Neurofibrillary Tangles as a
Target for Developing New
Therapeutics for AD*
Duration: 2002

*Apolipoprotein E as a Target for
Developing New Therapeutics
for Alzheimer's Disease*
Duration: 2003

*Facilitating the Development
of PET Diagnostics for
Alzheimer's Disease*
Duration: 2003

*Creating New Models of
Alzheimer's Disease*
Duration: 2003

*Fourth Annual
Investigators' Meeting*
Duration: 2003

*New Directions in
Neuroprotection Basics: Basic
Mechanisms, Molecular Targets
and Treatment Strategies*
Duration: 2004

*Fifth Annual
Investigators' Meeting*
Duration: 2004

*Sixth Annual Alzheimer's
Drug Discovery Conference*
Duration: 2005

*Neurogenesis as a Therapeutic
Strategy for Cognitive Aging
and Alzheimer's Disease*
Duration: 2005

ALZHEIMER'S DRUG DISCOVERY FOUNDATION

Summarized Balance Sheet As of December 31, 2005

Assets	
Cash	\$ 1,074,314
Receivables and Other Assets	197,743
Total Assets	\$ 1,272,057
Liabilities and Net Assets	
Payables and Accrued Liabilities	110,287
Net Assets	1,161,770
Total Liabilities and Net Assets	\$ 1,272,057

Summarized Operational Information For The Year Ended December 31, 2005

Support and Revenues	
Support -	
Contributions and Grants	\$ 1,560,538
Revenues -	
Investment and Other Income	35,437
Total Support and Revenues	1,595,975
Expenses	
Program-Related Services	610,148
Fund Raising and Development	147,052
Management and General	64,301
Total expenses	821,501
Change in net assets	774,474
Net assets, January 1, 2005	387,296
Net assets, December 31, 2005	\$ 1,161,770

The accompanying financial information has been derived from the Foundation's 2005 Audited Financial Statements and is presented here in condensed form.

INSTITUTE FOR THE STUDY OF AGING, INC.

Summarized Balance Sheet As of December 31, 2005

Assets	
Cash	\$ 3,032,737
Program-Related Investments	1,398,722
Property and Equipment	86,709
Other Assets	72,080
Total Assets	\$ 4,590,248
Liabilities and Net Assets	
Payables and Accrued Liabilities	9,830
Net Assets	4,580,418
Total Liabilities and Net Assets	\$ 4,590,248

Summarized Operational Information For The Year Ended December 31, 2005

Support and Revenues	
Support -	
Contributions	\$ 3,451,286
Revenues -	
Investment Income	57,532
Total Support and Revenues	3,508,818
Expenses	
Grants	2,066,353
Program-Related Services	1,825,612
Management and General / Development	264,385
Total expenses	4,156,350
Change in net assets	(647,532)
Net assets, January 1, 2005	5,227,950
Net assets, December 31, 2005	\$ 4,580,418

The accompanying financial information has been derived from the Institute's 2005 Audited Financial Statements and is presented here in condensed form.

2005 CONTRIBUTING PARTNERS

We gratefully acknowledge the following partners for their generosity and support. Through their dedication, we are able to advance our mission of accelerating drug discovery research.

Contributions of \$1,000,000 and Above

ESTÉE LAUDER FAMILY

Contributions of \$100,000 and Above

ÉLAN PHARMACEUTICALS, INC. FOREST PHARMACEUTICALS, INC.

Contributions of \$10,000 and Above

MR. AND MRS. ROBERT E. BARNHILL, JR.	MS. NANCY CORZINE	ORTHO-McNEIL	THE ROBERT E. & DOROTHY Z. BARNHILL FAMILY FUND
MR. AND MRS. JOHN AND LIZBETH COONEY	DR. AND MRS. JACK AND JOY FISHMAN	NEUROLOGICS, INC./JANSSEN MEDICAL AFFAIRS, LLC	MR. AND MRS. RANDAL SANDLER AND LIZABETH FURMAN SANDLER
	THE HAZEN POLSKY FOUNDATION	PFIZER, INC.	

Contributions of \$1,000 and Above

ACUMEN PHARMACEUTICALS, INC.	THE DANIEL M. AND BROOKE G. NEIDICH FOUNDATION	MARTEK BIOSCIENCES CORPORATION	DR. AND MRS. FRED AND LESLYE SUGAR
BLOOMBERG LC	DAYTON COLES	MERCK & CO.	MS. AMY G. TREITEL
THE CLAIRE & THEODORE MORSE FOUNDATION	MS. DONNER SELMA	NEUROCHEM INC.	WYETH PHARMACEUTICALS
THE DALIO FAMILY FOUNDATION INC.	ESTÉE LAUDER - OEVEL PLANT GRAPHIC EXPRESSION INC.	THE JON AND SUSAN ROTENSTREICH FOUNDATION	

Contributions of \$100 and Above

MS. RACHEL BALSAM	THE HERRING FINN FOUNDATION	DR. AND MRS. STEVEN LASSER	MR. GARY R. SILVERMAN
MS. NANCY M. BAYCROFT	THE JEWISH COMMUNAL FUND	MS. BONNIE LEISLE	THE LEONARD & EVELYN LAUDER FOUNDATION
MR. AND MRS. BOILY THOMAS	THE DOUGLAS AND ELIZABETH KOER FOUNDATION	THE REGAL FAMILY	THE PEDIATRIC DENTISTRY, LTD. STAFF
DR. FOTINI M. DIONISOPOULOS		MR. AND MRS. KENNETH SHERMAN	
MR. AND MRS. MICHALE AND CYNTHIA GIBBONS			

Other Contributing Partners

DR. AND MRS. STEPHEN DEUTSCH	MS. ROSALYN GLICK	MR. AND MRS. ALAN AND NANCY KAUFMAN	MR. AND MRS. DANIEL AND IVY MARWIL
MR. AND MRS. PHILIP AND BARBARA FALCONE	MR. AND MRS. SAMUEL AND LUCILLE IRVING	MR. AND MRS. PETER KRULEWITCH	MS. ROBIN PEARL AND MR. JONATHAN KARGMAN
MR. AND MRS. ROBERT GILLEN	MR. AND MRS. MICHAEL AND MINDY ISAACS	MR. AND MRS. NANCY AND STEVE LERNER	MR. STEVEN PEISER-BUS AND MRS. LIBBY PEISER
MR. AND MRS. RENE AND JAY GLASS	MS. JUDITH C. ISROFF	MR. AND MRS. ALFRED AND BONNIE MARGULIES	DR. AND MRS. STUART ROSS
	MRS. JEANNE G. KASKEY		

Partnership Sponsored Programs

FOREST LABORATORIES INC.	PACIFICARE HEALTH SYSTEMS, INC.
HEALTHCARE DIMENSIONS, INC.	ZOE FINCH TOTTEN

MESSAGE FROM THE DIRECTOR OF DEVELOPMENT




Suzanne Grossberg
Director of Development

Fulfilling the Lauder family goal of engaging others to participate in the ADDF mission has been one of the greatest rewards of my lifetime. Throughout 2005, I spoke with hundreds of people and it seemed that one out of every two that I met told me they had a loved one who was suffering from AD or past way from it. At first, they were hesitant in disclosing their experiences, but after hearing about our foundation they spoke more freely and offered suggestions.

With the help of many, we were able to recruit four exceptional people to our new Board of Directors. We also started an Advisory Council with three highly experienced individuals from the healthcare and biotechnology industries. Additionally, we formed a Business Development Committee to assist us with public relations, special events and networking. All of these dedicated people have generously taken the time to act as ADDF ambassadors and rally others to work with us.

As part of our partnership-building and fundraising strategy, we reached out to numerous corporations, foundations and government agencies. They responded so positively that we nearly doubled our anticipated financial goal for 2005, raising \$2,455,259.

Concluding my first year at the ADDF, I am convinced that working together is the only way we will be able to cure AD. I am grateful for everyone who has collaborated with us and look forward to building upon our relationships, as well as initiating new ones, in 2006.



Accelerating drug discovery for Alzheimer's disease
through venture philanthropy



Alzheimer's Drug Discovery Foundation

1414 Avenue of the Americas, Suite 1502

New York, NY 10019

P 212 935 2402 F 212 935 2408

www.AlzDiscovery.org

ADDF Grid
L

